/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

H

Hideyuki Mishima

Aichi Medical University(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

244

Papers

2.0K

Citations

21

h-index

51

i10-index

Hideyuki Mishima is an academic researcher from Aichi Medical University. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Cancer Treatment and Pharmacology & Gastric Cancer Management and Outcomes. The author has an h-index of 21, co-authored 208 publications.

Research Topics

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Gastric Cancer Management and Outcomes Colorectal and Anal Carcinomas Colorectal Cancer Surgical Treatments

Papers by this author

works

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy

2013 · Cancer Chemotherapy and Pharmacology · 105 citations

https://doi.org/10.1007/s00280-013-2306-7

Toru Kono Taishi Hata Satoshi Morita Yoshinori Munemoto

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study

2019 · British Journal of Cancer · 26 citations

https://doi.org/10.1038/s41416-019-0410-0

Naohiro Tomita Katsuyuki Kunieda Atsuyuki Maeda Chikuma Hamada

Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations

2014 · Molecular Diagnosis & Therapy · 21 citations

https://doi.org/10.1007/s40291-014-0083-6

Hiromichi Maeda Shoichi Hazama Shavkat Abdiev Ken Okamoto

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study

2017 · ESMO Open · 20 citations

https://doi.org/10.1136/esmoopen-2016-000135

Hideo Baba Yasuhide Yamada Daisuke Takahari Hiroshi Matsumoto

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)

2016 · Cancer Chemotherapy and Pharmacology · 15 citations

https://doi.org/10.1007/s00280-016-3203-7

Masato Nakamura Toru Aoyama Keiichiro Ishibashi Akihito Tsuji

Efficacy of celecoxib as preemptive analgesia for patients undergoing laparoscopic inguinal hernia repair: a randomized trial

2021 · Surgery Today · 7 citations

https://doi.org/10.1007/s00595-020-02199-w

Takuya Saito Shigeyoshi Iwamoto Kenta Murotani Atsushi Hashimoto

Research topics

topics

Colorectal Cancer Treatments and Studies

Cancer Treatment and Pharmacology

Gastric Cancer Management and Outcomes

Colorectal and Anal Carcinomas

Colorectal Cancer Surgical Treatments

Chat about Author

Papers

Chat

Click to start Chat